Mumbai, April 27, 2026: Rallis India Limited (A TATA Enterprise) is a leading player in the Indian agri inputs industry announced its financial results for the quarter and year ended March 31, 2026.
Announcing the results, Dr. Gyanendra Shukla, Managing Director & CEO, Rallis India Limited, said,
The Company delivered a steady performance during FY26, supported by broad based growth across key businesses and improvement in margins. The Company reported its highest-ever EBITDA, driven by volume growth and cost optimisation initiatives.
During the year, revenue stood at ₹ 2,897 crore, compared to ₹ 2,663 crore in the previous year, reflecting growth driven by performance across Crop Care, Seeds, and B2B businesses. Profit After Tax stood at ₹ 184 crore, compared to 3 125 crore in the previous year.
During the Quarter, the Company recorded revenue of ₹ 456 crore, compared to 3 430 crore in Q4 FY25. The performance reflected mixed demand conditions across crops and geographies, with lower pest pressure in certain crops impacting demand, while select segments continued to show resilience. The Company recorded moderate growth during the quarter, supported by volume expansion and stable pricing.
Business Performance: Q4 & FY26
During FY26, the Crop Care business grew by 8%, with the Domestic Formulations business delivering 5% growth driven by steady performance across key brands.
The B2B Exports business including Custom Synthesis Manufacturing (CSM) grew by 17%, supported by volume expansion in the International Business Division and improved realisations across key molecules. The Soil and Plant Health (SPH) segment delivered a growth of 8% despite regulatory challenges relating to Biostimulants, supported by focused product placement and demand generation initiatives.
The Seeds business grew by 15%, driven by strategic planning and execution amidst supply constraints and demand challenges in key crops like Cotton and Mustard.
During Q4 FY26, the Company recorded revenue growth of 6% year-on-year, driven by 5% volume growth and 1% price growth. The Crop Care business grew by 5%, with the B2C segment delivering 15% growth, while the B2B business declined by 7% due to lower volumes. The Seeds business delivered strong growth of 23% during the quarter.
Key Highlights: Q4 FY26
In Crop Protection, the business launched two new insecticide products (Fiplam and Alstor), strengthening the product portfolio
Achieved highest-ever production levels of select products, driven by improved manufacturing efficiency and operational excellence initiatives
Continued focus on digital initiatives, enhancing farmer and retailer engagement and improving market reach
In Seeds, the business launched two new products across core crops.
Management Comment
Commenting on the performance, Dr. Gyanendra Shukla, Managing Director & CEO, Rallis India Limited, said: “FY26 reflects our continued focus on strengthening the business through focused execution, portfolio expansion, and customer engagement. While demand conditions varied across the year, we remained focused on improving margins and driving growth across businesses. As we move forward, we will continue to build on our product portfolio, digital capabilities, and innovation pipeline to drive sustainable growth.”
About Rallis India:
Rallis India Limited is a subsidiary of Tata Chemicals Limited and a part of over US$ 180 billion Tata Group. Rallis is one of India’s leading agri science companies, with more than 77 years of experience in serving rural markets with a comprehensive portfolio of products/solutions for Indian farmers. Rallis is known for its deep understanding of Indian agriculture, sustained connect with farmers, quality agrochemicals, branding and marketing expertise along with its strong product portfolio in seeds and crop care which is available through a vast distribution network of 7,200 dealers and over 95,000 retailers across India. Rallis has marketing alliances with several multinational agrochemical companies. Rallis is also known for its manufacturing capabilities and ability to develop new processes and formulations; hence it is considered a preferred partner for contract manufacturing by leading global corporations.